US03828A1016 - Common Stock
2.67 +0.03 (+1.14%)
After market: 2.58 -0.09 (-3.37%)
APPLIED THERAPEUTICS INC
NASDAQ:APLT (9/28/2023, 7:00:00 PM)After market: 2.58 -0.09 (-3.37%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. The company is headquartered in New York City, New York and currently employs 22 full-time employees. The company went IPO on 2019-05-09. The firm is focused on developing a pipeline of product candidates against validated molecular targets in indications of high unmet medical need. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. The Company’s product candidates include AT-007, AT-001, and AT-003. Its AT-007 is a central nervous system (CNS) penetrant ARI for the treatment of CNS rare diseases, including Galactosemia, sorbitol dehydrogenase (SORD) deficiency, and PMM2-CDG. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is being developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR).
APPLIED THERAPEUTICS INC
545 5Th Avenue, Suite 1400
New York City NEW YORK 10017
CEO: Shoshana Shendelman
The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the efficacy of AT-001 (caficrestat) on cardiac functional capacity in patients...
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Which stocks are experiencing notable movement on Tuesday?
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Here you can normally see the latest stock twits on APLT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.